酚妥拉明、多巴胺及卡托普利三联疗法治疗肺源性心脏病的效果及其对患者心功能的影响  

Effect of Triple Therapy of Phentolamine,Dopamine and Captopril in the Treatment of Pulmonary Heart Disease and Its Impact on Cardiac Function of Patients

作　　者：陈雅丽[1] 闫佩佩[1] 白雪洋[2] 王丽蕊[3] CHEN Yali;YAN Peipei;BAI Xueyang;WANG Lirui(1^(st)General Department(2),the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450015,China;Cardiology Department,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450015,China;Surgical ICU,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450015,China)

机构地区：[1]郑州大学第一附属医院综合科一(2),河南郑州450015 [2]郑州大学第一附属医院心内科,河南郑州450015 [3]郑州大学第一附属医院外科ICU,河南郑州450015

出　　处：《临床医学工程》2022年第4期471-472,共2页Clinical Medicine & Engineering

摘　　要：目的探讨酚妥拉明、多巴胺及卡托普利三联疗法治疗肺源性心脏病的临床效果。方法60例肺源性心脏病患者随机分为两组,对照组给予常规对症治疗,观察组在对照组基础上给予酚妥拉明、多巴胺及卡托普利三联疗法。比较两组的治疗效果、心功能及生活质量。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的RVID、PAP均低于对照组,LVEF、生活质量评分均高于对照组(P<0.05)。结论酚妥拉明、多巴胺及卡托普利三联疗法治疗肺源性心脏病的效果确切,能够显著改善患者的心功能,提高患者的生活质量。Objective To explore the clinical effect of triple therapy of phentolamine,dopamine and captopril in the treatment of pulmonary heart disease.Methods 60 patients with pulmonary heart disease were randomly divided into two groups.The control group received routine symptomatic treatment,and the observation group received triple therapy of phentolamine,dopamine and captopril on the basis of the control group.The therapeutic effect,cardiac function and quality of life were compared between the two groups.Results The total effective rate of treatment of the observation group was higher than that of the control group(P<0.05).After treatment,the RVID and PAP of the observation group were lower than those of the control group,and the LVEF and quality of life score were higher than those of the control group(P<0.05).Conclusions Triple therapy of phentolamine,dopamine and captopril in the treatment of pulmonary heart disease has exact effect,and can obviously improve the cardiac function and quality of life of patients.

关 键 词：酚妥拉明 多巴胺 卡托普利 肺源性心脏病 

分 类 号：R541.5[医药卫生—心血管疾病]